Health and Me on MSN

This widely used dementia drug may raise stroke risk in all patients, study finds

A large UK study of over 165,000 dementia patients finds risperidone raises stroke risk in all users, prompting concerns over prescribing, monitoring, and dementia care guidelines. Keep reading for ...

Widely Used Dementia Drug Raises Stroke Risk in All Patients

New safety study links sedative use to increased stroke risk. A large UK study involving more than 165,000 people with dementia has found that the drug risperidone increases the risk of stroke in all ...
Seeking Alpha

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA ...
Nasdaq

Teva Pharmaceuticals Reports Positive Real-World Outcomes for UZEDY® (risperidone) in Schizophrenia Treatment Compared to Second-Generation Oral Antipsychotics

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...
Nasdaq

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients ...

PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)-- Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell ...
Healio

Weekly risperidone achieves similar drug levels as daily dose in phase 3 trial

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Weekly risperidone delivered via the Lynx platform ...
Monthly Prescribing Reference

Study Shows Weekly Oral Risperidone Comparable to Daily Doses for Schizophrenia

LYN-005 is an investigational long-acting oral capsule formulation of the atypical antipsychotic risperidone. Positive data were announced from a phase 3 study comparing the pharmacokinetic (PK) ...